埃替格韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺与华法林合用期间患者国际标准化比值异常升高：一例报告 - Suppr

Suppr

超能文献

Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.

作者信息

Malagnino Vincenzo, Cerva Carlotta, Teti Elisabetta, Maffongelli Gaetano, Andreoni Massimo, Sarmati Loredana

机构信息

Clinic of Infectious Diseases, Tor Vergata University, Rome, Italy.

出版信息

AIDS. 2019 Feb 1;33(2):360-361. doi: 10.1097/QAD.0000000000002097.

DOI:10.1097/QAD.0000000000002097

PMID:30489284

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6319575/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ebd/6319575/57c9c2e82ca4/aids-33-360-g001.jpg

相似文献

Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.埃替格韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺与华法林合用期间患者国际标准化比值异常升高：一例报告

AIDS. 2019 Feb 1;33(2):360-361. doi: 10.1097/QAD.0000000000002097.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。

Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.一项多中心、开放标签、3b 期、随机试验：在 HIV-1 病毒学抑制的 60 岁及以上人群中，将包含富马酸替诺福韦二吡呋酯的方案转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂方案时，对骨矿物质密度的影响。

Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺：用于治疗人类免疫缺陷病毒 1 型感染的综述。

Drugs. 2016 Jun;76(9):957-68. doi: 10.1007/s40265-016-0586-z.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯、艾维雷韦、考比司他、恩曲他滨复方制剂，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗：两项随机、双盲、III 期、非劣效性试验。

Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.在病毒学抑制的 HIV 成人患者中，将依维莫司、考比司他、恩曲他滨和替诺福韦酯与恩曲他滨和替诺福韦酯的非核苷类逆转录酶抑制剂转换与继续使用非核苷类逆转录酶抑制剂（STRATEGY-NNRTI）：一项随机、开放标签、3b 期非劣效性试验的 48 周结果。

Lancet Infect Dis. 2014 Jul;14(7):590-9. doi: 10.1016/S1473-3099(14)70796-0. Epub 2014 Jun 5.

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.在病毒学抑制的 HIV 成人患者中，与继续使用利托那韦增效蛋白酶抑制剂联合恩曲他滨和替诺福韦相比，简化的艾维雷韦/考比司他/恩曲他滨/替诺福韦与恩曲他滨和替诺福韦的联合方案（STRATEGY-PI）：一项随机、开放标签、3b 期、非劣效性试验的 48 周结果。

Lancet Infect Dis. 2014 Jul;14(7):581-9. doi: 10.1016/S1473-3099(14)70782-0. Epub 2014 Jun 5.

Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂用于人类免疫缺陷病毒暴露后预防。

Clin Infect Dis. 2020 Feb 14;70(5):943-946. doi: 10.1093/cid/ciz577.

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.初治HIV-1患者接受埃替拉韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺治疗48周后罕见出现耐药性。

HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.在初治的HIV-1感染受试者中，使用埃替格韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺或埃替格韦/考比司他/恩曲他滨/替诺福韦酯进行96周治疗后耐药性出现频率较低。

Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11.

引用本文的文献

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy-Update 2022: Systematic Review.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者中药物相互作用的临床相关性——2022年更新：系统评价

Pharmaceutics. 2023 Oct 18;15(10):2488. doi: 10.3390/pharmaceutics15102488.

本文引用的文献

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.替诺福韦酯转换为替诺福韦艾拉酚胺的患者体内血浆和细胞内药代动力学。

AIDS. 2018 Mar 27;32(6):761-765. doi: 10.1097/QAD.0000000000001744.

An unexpected interaction between warfarin and cobicistat-boosted elvitegravir.华法林与考比司他增强的埃替格韦之间意外的相互作用。

AIDS. 2015 May 15;29(8):985-6. doi: 10.1097/QAD.0000000000000630.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验